Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
1. A compound of formula CLVII or a salt, ester, or prodrug thereof:
wherein
k, l, and o are independently 0, 1, 2, 3, 4, 5, or 6;
W is C or N;
X 1 , X 2 , X 3 , X 4 , and X 5 are independently selected from the group consisting of —H, —OH, —OR, —F, —Cl, —Br, —I, —NO 2 , —NO, —N(R) 2 , —N(R) 3 + , —C(O)R,—C(O)OR, —CHO, —C(O)NH 2 , —C(O)SR, —CN, —S(O) 2 R, —SO 3 R, —SO 3 H, —SO 2 N(R) 2 , —S═O, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
Y 1 is selected from the group consisting of O, NH, NR a , S, and CH 2 ;
Y 2 is selected from the group consisting of O, NH, NR b , S, and CH 2 ;
R, R a , and R b are independently selected from the group consisting of C 1 to C 6 alkyl, C 3 to C 6 cycloalkyl, CH 2 —C 3 -C 6 cycloalkyl, phenyl, tolyl, and benzyl;
Z 1 and Z 2 are independently selected from the group consisting of C, P—OH, S, and S═O;
U is selected from the group consisting of —NR c C(O)OR e , —NR c C(O)NR f R e , —NR c C(O)SR e , —NR c P(O)(OH)R e , —NR c P(O)(OH)OR e , —NR c P(O)(OH)NR f R e , —NR c P(O)(OH)SR e , —NR c S(O)R e , —NR c S(O)OR e , —NR c S(O)NR f R e , NR c S(O)SR e , —NR c S(O) 2 R e , —NR c S(O) 2 OR e , NR c S(O) 2 NR f R e , —NR c S(O) 2 SR e , —OC(O)OR e , —OC(O)NR f R e , —OC(O)SR e , —OP(O)(OH)R e , —OP(O)(OH)OR e , —OP(O)(OH)NR d R e , —OP(O)(OH)SR e , —OS(O)R e , —OS(O)OR e , —OS(O)NR d R e , —OS(O)SR e , —OS(O) 2 R e , —OS(O) 2 OR e , —OS(O) 2 NR d R e , —OS(O) 2 SR, and —C(O)R c ;
R c and R d are independently selected from the group consisting of H, C 1 to C 12 alkyl, C 1 to C 12 haloalkyl, C 3 to C 6 cycloalkyl, (CH 2 ) m —C 3 -C 6 cycloalkyl, C 2 to C 6 heterocycloalkyl, (CH 2 ) m —C 2 -C 6 heterocycloalkyl, benzyl, aryl, (CH 2 ) m -aryl, heteroaryl, (CH 2 ) m -heteroaryl, and substituted derivatives thereof, or R c and R d taken together with the N atom to which they are bonded form a 3- to 8-membered heterocyclic ring;
m is 1, 2, 3, 4, 5, or 6;
R f is selected from the group consisting of H, C 1 to C 12 alkyl, C 1 to C 12 haloalkyl, C 3 to C 6 cycloalkyl, (CH 2 ) m —C 3 -C 6 cycloalkyl, C 2 to C 6 heterocycloalkyl, (CH 2 ) m —C 2 -C 6 heterocycloalkyl, benzyl, aryl, (CH 2 ) m -aryl, heteroaryl, (CH 2 ) m -heteroaryl, and substituted derivatives thereof; and
R e is selected from the group consisting of H, C 1 to C 12 alkyl, C 1 to C 12 haloalkyl, C 3 to C 6 cycloalkyl, (CH 2 ) m —C 3 -C 6 cycloalkyl, C 2 to C 6 heterocycloalkyl, (CH 2 ) m —C 2 -C 6 heterocycloalkyl, benzyl, aryl, (CH 2 ) m -aryl, heteroaryl, (CH 2 ) m -heteroaryl,
and substituted derivatives thereof.
2. The compound of claim 1 having a formula LXIII, or a salt, ester, or prodrug thereof:
wherein k, l, o, W, X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , Z 1 , Z 2 , and U are as defined in claim 1 .
3. The compound of claim 1 or a salt, ester, or prodrug thereof, wherein R e is substituted aryl having a formula:
X 5 and X 6 are independently selected from the group consisting of —H, —OH, —OR, —F, —Cl, —Br, —I, —NO 2 , —NO, —N(R) 2 , —N(R) 3 ± , —C(O)R, —C(O)OR, —CHO, —C(O)NH 2 , —C(O)SR, —CN, —S(O) 2 R, —SO 3 R, —SO 3 H, —SO 2 N(R) 2 , —S═O, aryl, substituted aryl, and heteroaryl; and
R is selected from the group consisting of C 1 to C 6 alkyl, C 3 to C 6 cycloalkyl, CH 2 —C 3 -C 6 cycloalkyl, phenyl, tolyl, and benzyl.
4. The compound of claim 1 or a salt, ester, or prodrug thereof, wherein R e is selected from the group consisting of 4-chlorophenyl, 4-fluorophenyl, 2,5-dihydroxyphenyl, 2,5-dimethoxyphenyl, 3-(trifluoromethyl)phenyl, 4-chloro-2-fluorophenyl, 2,4-dihydroxyphenyl, 2,4-dimethoxyphenyl, 3,5-dichloro-4-hydroxyphenyl, 3,5-difluoro-4-hydroxyphenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 3,5-dichloro-4-methoxyphenyl, 3,5-difluoro-4-methoxyphenyl, 4-methylphenyl, phenyl, naphthyl, biphenyl, indolyl, methyl, 2-chlorophenyl, (1-trichloromethyl-1-methyl)ethyl, 1,1-dimethylethyl, 2,2-dimethylpropyl, benzyl, (2-pyridinyl)methyl, (3-pyridinyl)methyl, (4-pyridinyl)methyl, and
5. The compound of claim 1 having a formula XCI or a salt, ester, or prodrug thereof:
wherein R e is selected from the group consisting of 4-chlorophenyl, 4-fluorophenyl, 2,5-dihydroxyphenyl, 2,5-dimethoxyphenyl, 3-(trifluoromethyl)phenyl, 4-chloro-2-fluorophenyl, 2,4-dihydroxyphenyl, 2,4-dimethoxyphenyl, 3,5-dichloro-4-hydroxyphenyl, 3,5-difluoro-4-hydroxyphenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 3,5-dichloro-4-methoxyphenyl, 3,5-difluoro-4-methoxyphenyl, 4-methylphenyl, phenyl, and methyl.
6. The compound of claim 1 having a formula XCII or a salt, ester, or prodrug thereof:
wherein R e is selected from the group consisting of phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, (1-trichloromethyl-l-methyl)ethyl, 3-(trifluoromethyl)phenyl, 2,2-dimethylpropyl, benzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2-bromobenzyl, 3-bromobenzyl, 4-bromobenzyl, 2-iodobenzyl, 3-iodobenzyl, 4-iodobenzyl, (2-pyridinyl)methyl, (3-pyridinyl)methyl, (4-pyridinyl) methyl, C 1 to C 6 alkyl, and
7. The compound of claim 1 , wherein R c , R d , and R f are independently selected from the group consisting of phenyl, tolyl, naphthyl, biphenyl, and indolyl.
8. The compound of claim 1 having a formula CL or a salt, ester, or prodrug thereof:
wherein X 1 and X 3 are independently selected from the group consisting of —H and —OH; U is selected from the group consisting of —NHC(O)OR e and —NHC(O)NHR e ; and R e is selected from the group consisting of 1-naphthyl, 2-naphthyl, 4-biphenyl-1-yl, and substituted derivatives thereof.
9. A compound having a formula selected from the group consisting of LXIV, LXXXI, LXXXVI, LXXXIX, XC, C, CIII, CIV, CXII, CXIII, CXIV, CXIX, CXX, CXXI, CXXXV, CXXXVI, CXXXVII, CXXXVIII, CXXXIX, CLX, CLXI, and salts, esters, or prodrugs thereof:
10. The compound of claim 1 or a salt, ester, or prodrug thereof, wherein U is —NR c C(O)OR e .
11. A composition comprising the compound according to claim 1 or a salt, ester, or prodrug thereof and a pharmaceutically acceptable carrier.
12. A method of increasing circulating high density lipoprotein (HDL) in a subject, comprising administering to said subject a plasminogen activator inhibitor-1 (PAI-1) inhibitor compound according to claim 1 in an amount effective to increase HDL.
13. A method of decreasing circulating very low density lipoprotein (VLDL) in a subject, comprising administering to said subject a plasminogen activator inhibitor-1 (PAI-1) inhibitor compound according to claim 1 in an amount effective to decrease VLDL.
14. The method of claim 12 or 13 , wherein the subject is human.
15. The method of claim 12 or 13 , wherein the PAI-1 inhibitor decreases PAI-1 binding to apolipoprotein E (ApoE).
16. The method of claim 12 or 13 , wherein the PAI-1 inhibitor decreases PAI-1 binding to apolipoprotein A (ApoA).
17. The method of claim 12 or 13 , wherein the PAI-1 inhibitor decreases PAI-1 binding to VLDL.
18. The method of claim 12 or 13 , wherein the PAI-1 inhibitor binds to PAI-1 in the presence of vitronectin.
19. The method of claim 12 or 13 , wherein the PAI-1 inhibitor binds to PAI-1 in the presence of urokinase type plasminogen activator (uPA).
20. A method of modulating cholesterol and/or lipid uptake comprising the step of administering a PAI- 1 inhibitor compound according to claim 1 in an amount effective to modulate cholesterol and/or lipid uptake.
21. A method of modulating cholesterol and/or lipid clearance comprising the step of administering a plasminogen activator inhibitor-1 (PAI-1) inhibitor compound according to claim 1 in an amount effective to inhibit very low density lipoprotein (VLDL) or apolipoprotein E (ApoE) or apolipoprotein A (ApoA) binding to VLDL-R and modulate cholesterol and/or lipid clearance.
22. A method of modulating cholesterol and/or lipid clearance comprising the step of administering a plasminogen activator inhibitor-1 (PAI-1) inhibitor compound according to claim 1 in an amount effective to affect HDL or apolipoprotein E (ApoE) or apolipoprotein A (ApoA) binding to an ApoA receptor and modulate cholesterol and/or lipid clearance.